CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) shares in Thousands, $ in Thousands		Total	Common Stock	Additional Paid-In Capital	Treasury Stock	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total UpHealth, Inc. Stockholders’ Equity	Noncontrolling Interests
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period (in shares)	[1]				0
Balance at beginning of period (in shares) at Dec. 31, 2021	[1]		14,428
Balance at beginning of period at Dec. 31, 2021	[1]	$ 333,843	$ 1	$ 665,474	$ 0	$ (343,209)	$ (3,802)	$ 318,464	$ 15,379
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity award activity, net of shares withheld for taxes (in shares)	[1]		37
Equity award activity, net of shares withheld for taxes	[1]	(68)		(68)				(68)
Stock-based compensation		1,374		1,374				1,374
Net income (loss)		(17,705)				(17,445)		(17,445)	(260)
Foreign currency translation adjustments		(1,377)					(1,377)	(1,377)
Balance at end of period (in shares) at Mar. 31, 2022	[1]		14,465
Balance at end of period (in shares) at Mar. 31, 2022	[1]				0
Balance at end of period at Mar. 31, 2022	[1]	316,067	$ 1	666,780	$ 0	(360,654)	(5,179)	300,948	15,119
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period (in shares)	[1]				0
Balance at beginning of period (in shares)					170
Balance at beginning of period (in shares) at Dec. 31, 2022			15,054
Balance at beginning of period at Dec. 31, 2022		106,137	$ 2	688,355	$ (17,000)	(566,209)	0	105,148	989
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity award activity, net of shares withheld for taxes (in shares)			80
Equity award activity, net of shares withheld for taxes		(3)		(3)				(3)
Issuance of common stock in connection with private placement, net of issuance costs (in shares)			1,650
Issuance of common stock in connection with private placement, net of issuance costs		4,155		4,155				4,155
Stock-based compensation		989		989				989
Net income (loss)		(7,635)				(8,083)		(8,083)	448
Distribution to noncontrolling interests		(44)							(44)
Foreign currency translation adjustments		0
Balance at end of period (in shares) at Mar. 31, 2023			16,784
Balance at end of period (in shares) at Mar. 31, 2023					170
Balance at end of period at Mar. 31, 2023		$ 103,599	$ 2	$ 693,496	$ (17,000)	$ (574,292)	$ 0	$ 102,206	$ 1,393
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period (in shares)					170

[1] Amounts as of March 31, 2022 and before that date differ from those published in our prior condensed consolidated financial statements as they were retrospectively adjusted as a result of the Reverse Stock Split (as described below in Note 1, Organization and Business). Specifically, the number of common shares outstanding during periods before the Reverse Stock Split are divided by the exchange ratio of 10:1, such that each ten shares of common stock were combined and reconstituted into one share of common stock effective December 8, 2022.